Compare Enveric Biosciences Inc (ENVB) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wynn Resorts, Limited — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Wynn Resorts, Limited trades at $106.96 (market cap $10.79B). The key difference: Wynn Resorts, Limited is far larger — about 1740.3× Enveric Biosciences Inc's market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | WYNN | |
|---|---|---|
Market Cap | $6.20M | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $133.34 |
52-Week Low | $1.27 | $94.37 |
Enterprise Value | $1.30M | $21.03B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wynn Resorts (WYNN) trades at $102.50, showing minimal daily movement with a slight 0.04% decline. The stock maintains a bullish technical outlook with strong institutional support, though faces fundamental challenges including declining net margins from 11.17% in 2023 to 4.58% in 2025. Recent Q2 2026 earnings beat expectations with $1.24 EPS versus $0.992 estimates, driven by Macau performance, while Las Vegas operations show weakness. The company faces significant capital expenditure pressures from UAE and Macau expansion projects.
Wynn presents a mixed investment case with 64% analyst buy ratings and $133 consensus target suggesting 30% upside, but faces execution risks from $1.6B+ annual capex and high debt load. The stock's valuation at 25x P/E appears reasonable given recovery potential, though margin compression and project timing create near-term uncertainty. Key catalysts include Macau recovery sustainability and successful UAE project execution by 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
